In addition, latent and lytic proteins alter NF-κB to promote immune evasion and tumor progression [85].‘in vitro’ and ‘in vivo’ studies have shown that inhibition of NF-κB can cause reactivaton of KSHV latency form, reducing tumorigenicity in PEL cells and endothelial cell transformation [86]. The gene discussed is NFKB1; the disease is neoplasm.